Metformin add-on for newly diagnosed leprosy treatment
Treatments studied
Part of Infections clinical trials.
This Phase 2 trial tests whether adding metformin to standard leprosy treatment (multidrug therapy, or MDT) helps people with multibacillary leprosy recover better and remain tolerable over 48 weeks. Participants also get monitored closely for side effects and safety issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (male or female).
- You were newly diagnosed with multibacillary leprosy and started MDT within the last 28 days.
- You can consent to the study and commit to visits and follow-up for 48 weeks.
- You have not taken metformin in the last 12 weeks (and you do not already take regular diabetes medicines like insulin).
- You do not have known diabetes, very low blood sugar history, or kidney/ liver lab results that are too abnormal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This trial tests a new vaccine (LEP-F1 + GLA-SE) to see if it is safe and helps the body fight leprosy. It is for healthy adults living in areas where leprosy is common.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a shorter treatment regimen for people who have both diabetes and a type of tuberculosis (TB) that is resistant to the usual medicines. The goal is to see if the new treatment works well and is safe for this group.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Hear when a new Leprosy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.